Zydus Cadila receives tentative approval from the USFDA for Ibrutinib Tablets

Zydus Cadila receives tentative approval from the USFDA for Ibrutinib Tablets Ahmedabad, 21 July, 2021 Zydus Cadila has received tentative approval from the USFDA to market Ibrutinib Tablets, in the strengths of 140 mg, 280 mg, 420 mg and 560 mg (US RLD: Imbruvica Tablets). Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphom a, chronic lymphocytic leukemia/ small lymphocytic lymphom a, and Waldenstrom's macroglobulinemia. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. For more information visit www.zyduscadila.com ***

The release as fetched from its publisher. zyduslife.com ↗